Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed

Documenti analoghi

• Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
  di: Camidge, D. Ross, et al.
  Pubblicazione: (2010)
• Diagnostic Assays for Identification of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer
  di: Weickhardt, Andrew J., et al.
  Pubblicazione: (2012)
• Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer
  di: Berge, Eamon M., et al.
  Pubblicazione: (2013)
• Native and rearranged ALK copy number and rearranged cell count in NSCLC: Implications for ALK inhibitor therapy
  di: Camidge, D. Ross, et al.
  Pubblicazione: (2013)
• Ceritinib in patients with advanced anaplastic lymphoma kinase–rearranged anaplastic large-cell lymphoma
  di: Richly, Heike, et al.
  Pubblicazione: (2015)